United States Diagnostic Imaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Diagnostic Imaging Market Trends and Insights

AI-Driven Workflow and Image Interpretation Adoption

FDA clearances for radiology algorithms climbed to 87 in 2024, a 40% jump over 2023. Health systems deploy these tools to reallocate radiologist time toward higher-revenue interventional cases. Aidoc’s triage platform cuts door-to-diagnosis time in stroke protocols by 30%.^{[1]Aidoc, “Ochsner Stroke Data One-Pager,” Aidoc, aidoc.com} Integration remains a hurdle because legacy PACS need custom APIs, and community hospitals lack informatics teams to validate outputs locally. The FDA now requires demographic-stratified performance metrics, a change that lengthens submissions but favors vendors embedding AI inside scanners. Consequently, platform manufacturers bundle algorithms with hardware, locking in service contracts and extending the reach of the United States diagnostic imaging market.^{[2]GE HealthCare, “CareIntellect,” GE HealthCare, gehealthcare.com}

Shift of Imaging Volumes to Outpatient and Ambulatory Settings

Ambulatory surgical centers deliver imaging at 30-40% lower cost per scan than hospital outpatient departments, attracting Medicare Advantage steerage that drives 13.32% CAGR through 2031. Site-neutral payment expansion in 2025 collapsed a USD 300 margin gap per lumbar spine MRI to roughly USD 50, pressuring hospital economics. Freestanding centers now perform 22% of non-hospital imaging, up from 18% in 2020, with growth strongest in states that repealed Certificate-of-Need laws. Hospitals respond by converting owned clinics into off-campus departments, but CMS tightened distance definitions, rendering 8% of legacy sites ineligible for hospital rates, a shift reshaping the United States diagnostic imaging market.

Rapid Penetration of Portable and Handheld Ultrasound/X-ray Systems

Handheld ultrasound shipments reached 180,000 units in 2025, a 60% rise since 2023, led by Butterfly iQ3 and GE HealthCare’s Vscan Air. Cloud-linked probes guide placement and flag anomalies, letting primary-care teams triage before ordering formal studies. Rural hospitals adopt portable X-ray to avoid patient transfers, reducing movement by 15%. CMS parity reimbursement for portable ultrasound removed a payment barrier. Accuracy gaps persist: a 2024 JACR study showed handhelds missed 12% of small pleural effusions versus 3% with cart systems.^{[3] Peter E. Morris, Anne K. Kelly, and Michael F. Morris, “Handheld Versus Cart-Based Ultrasound for Small Pleural Effusion Detection,” Journal of the American College of Radiology, jacr.org} New FDA guidance mandates transparency on algorithm training data, elevating standards for the United States diagnostic imaging market.

CMS Site-Neutral Payment Expansion Favoring Lower-Cost Imaging Sites

Equalized reimbursement for 11 new imaging codes in 2025 accelerated divestiture of hospital-owned centers, with systems selling 14% of off-campus sites to operators like RadNet and Akumin. Medicare Advantage prior-authorization funnels patients to preferred networks, raising independent center volumes. Hospitals attempt to preserve facility fees by rebranding clinics, but revised 250-yard rules curtail eligibility. These shifts redistribute capital and volume across the United States diagnostic imaging market.

Shortage of Radiologists and Technologists

A projected 35,600-radiologist gap by 2034 coincides with 12,000 unfilled technologist roles in 2025, raising reliance on USD 75-150 per-study teleradiology. Burnout affects 42% of radiologists, primarily from case overload and administrative tasks. AI triage saves 10-15% reading time but still demands human oversight. CMS caps on residency funding persist, and scope-of-practice expansions face state opposition, prolonging workforce scarcity that restrains the United States diagnostic imaging market.

Prolonged FDA Clearance Cycle for AI Algorithms and Novel Modalities

Average 510(k) review spans six months, while De Novo routes last 12 months, delaying commercialization. Draft 2025 guidance adds demographic-specific validation requirements, extending timelines further. Small firms lack regulatory infrastructure, tilting advantage toward incumbents. Breakthrough designation aided only 12 radiology devices in 2024, indicating limited relief. This bottleneck reduces the pace of innovation reaching the United States diagnostic imaging market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product and Services: Software Gains as Labor Costs Climb

Software and Services is projected to grow at a 16.73% CAGR, the quickest stride within the United States diagnostic imaging market. Cloud PACS, AI triage, and predictive-maintenance subscriptions appeal to hospitals facing workforce shortages. Imaging Systems and Equipment still accounts for 84.25% of 2025 revenue, anchored by MRI and CT units that cost USD 500,000-3 million. Deferred replacement cycles temper hardware growth but augment service contracts. 

Predictive maintenance via GE HealthCare’s CareIntellect curbs downtime by 30%, trimming USD 50,000 annually per scanner. Siemens’ AI-Rad Companion cuts reading time to four minutes, supporting under-resourced radiology groups. Portable X-ray and handheld ultrasound commoditize entry-level imaging, while Cancer Moonshot-backed PET expansion maintains niche high-end demand, shaping revenue streams within the United States diagnostic imaging market.

By Application: Neurology Surges on Alzheimer’s Diagnostics

Cardiology captured 33.63% of 2025 procedures, reflecting prevalent coronary disease and heart failure management. Neurology, driven by blood-based Alzheimer’s markers funneling patients to amyloid-PET, is forecast to grow at a 15.18% CAGR through 2031, the fastest pace in the United States diagnostic imaging market. Oncology benefits from broadened lung-screening criteria that doubled the eligible cohort to 14.5 million adults. 

Musculoskeletal MRI faces Medicare fee cuts, pushing centers toward higher-margin joints. Women's health imaging gains from earlier mammography age recommendations, raising tomosynthesis adoption to 75% of sites. Long-COVID keeps high-resolution CT in pulmonology workflows. AI lung-nodule tools trim false negatives by 20% yet require PACS integration funding, illustrating divergent adoption speeds inside the United States diagnostic imaging market.

By End User: Ambulatory Centers Capture Elective Volume

Hospitals retained 68.26% spending in 2025, but payer steerage lifts ambulatory centers at 13.32% CAGR, almost triple overall growth. Independent diagnostic testing facilities now perform 22% of scans and capitalize on lower cost structures under the Physician Fee Schedule. 

Physician offices invest in in-house imaging for ancillary revenue, yet Stark Law dictates ownership constraints. VA facilities depend on teleradiology to serve rural clinics but lag in equipment refresh. RadNet’s acquisition of 18 centers in 2024-25 consolidates coastal markets, while Akumin expands across Sun Belt states, evidencing competitive dynamism in the United States diagnostic imaging market.

By Technology: AI Adoption Accelerates Despite Integration Friction

Conventional systems still dominate with 84.13% 2025 share, but AI-enabled platforms are advancing at 13.58% CAGR. Deep-learning MRI reconstruction halves scan time, boosting throughput amid staffing constraints. Philips overlays real-time ultrasound guidance, cutting biopsy errors by 25%. 

Aidoc and RapidAI reached 1,000 and 1,600 U.S. hospitals, respectively, yet lack direct reimbursement, relying on subscriptions that health systems scrutinize. FDA clearance cycles provide incumbents an edge, but software-native entrants iterate faster, sustaining competition across the United States diagnostic imaging market.

Geography Analysis

Outpatient migration occurs nationwide but is most pronounced in Texas, Arizona, and Florida, where Certificate-of-Need repeals enabled a 25% surge in freestanding MRI and CT suites between 2023 and 2025. These Sun Belt states now host the densest cluster of new ambulatory imaging centers, attracting capital from private-equity groups that seek scale advantages in the United States diagnostic imaging market. 

Midwestern rural counties struggle with radiologist shortages and depend on portable ultrasound and teleradiology services. The VA prioritizes tele-interpretation contracts in Montana and the Dakotas, adding redundancy for critical findings communication. ARPA-H’s POSEIDON program sites early portable PET trials in Kansas and Iowa oncology clinics, although cyclotron access remains limited. 

Northeastern academic hubs - Massachusetts, New York, Pennsylvania - draw the bulk of federal research grants, concentrating photon-counting CT trials and Alzheimer’s neuroimaging studies. However, price transparency rules spur employers in these states to steer non-urgent scans to lower-cost New Hampshire and Delaware facilities, redistributing regional volume inside the United States diagnostic imaging market.

Regulatory Landscape

In the United States, diagnostic imaging systems and related software are regulated as medical devices by the FDA under the Center for Devices and Radiological Health (CDRH), with market entry commonly routed through 510(k) clearance and, for novel products, De Novo pathways. In June 2026, the FDA finalized a classification in 21 CFR 892.2055 for radiological machine learning-based quantitative imaging software that includes a predetermined change control plan, placing it in Class II with special controls and outlining a clearer regulatory pathway for certain AI-enabled imaging software updates.

Coverage and payment decisions also drive adoption, led by the Centers for Medicare and Medicaid Services (CMS) through the Physician Fee Schedule and the Hospital Outpatient Prospective Payment System (HOPPS). In April 2026, CMS and the FDA announced the RAPID coverage pathway to better align FDA market authorization with Medicare coverage for eligible Breakthrough Devices, while CMS reimbursement policy continues to evolve, including the 2027 HOPPS proposed rule released in July 2026, which proposes changes affecting nuclear medicine APC organization and diagnostic radiopharmaceutical payment thresholds.

Value Chain Analysis

The value chain runs from modality and component suppliers (detectors, coils, tubes, generators) to OEM design and manufacturing (CT, MRI, X-ray, ultrasound, nuclear medicine, mammography), software providers (PACS, VNA, RIS, AI triage and reconstruction), distributors and service organizations, and end users such as hospitals, IDTFs, ambulatory surgical centers, and physician offices. Post-sale revenue is reinforced through multi-year service contracts, uptime guarantees, and software subscriptions, and cloud enterprise imaging plus AI are increasingly positioned as operational infrastructure for managing throughput under staffing constraints.

Key pressure points include capital intensity for high-end modalities and supply-chain exposure from globally sourced components. Providers also face a growing need for interoperability and integration resources on-site. Policy-driven shifts in where imaging is performed, including site-neutral reimbursement reforms, influence procurement toward lower-cost settings, supporting standardized, scalable deployments and vendor bundles that reduce integration burden. Recent FDA clearances for advanced CT technologies, such as GE HealthCare's March 2026 510(k) clearance for Photonova Spectra photon-counting CT, show how innovation often flows from component advances to OEM platforms and then into provider purchasing cycles via upgrades, service, and software enablement.

Market Opportunities and Future Outlook

A near-term whitespace is forming at the intersection of AI-enabled imaging software and enterprise workflow, where clearer regulatory pathways and interoperability efforts can reduce deployment friction at scale. The FDA's June 2026 final classification for certain radiological machine learning-based quantitative imaging software under Class II special controls (21 CFR 892.2055) creates a more standardized compliance route for vendors using predetermined change control plans, supporting faster iteration cycles for imaging analytics that must work across heterogeneous PACS and scanner fleets.

Capacity expansion and service-line differentiation remain active opportunity areas as providers add advanced CT and MRI capability beyond major academic hubs. In June 2026, Roper St. Francis Healthcare completed a multi-year expansion at Berkeley Hospital in South Carolina that doubled imaging capacity by adding a second CT and a new MRI unit, while expanding interventional radiology services. In July 2026, UPMC Jameson expanded local access by adding cardiac CT and a wide-bore MRI system in Pennsylvania. Together, these investments highlight demand for turnkey deployments that combine equipment with staffing efficiency tools (cloud PACS, protocol automation, AI triage) and service support to keep new capacity productive amid radiologist and technologist shortages.